At PMV, we believe that by specifically targeting each mutant p53 we can fundamentally disrupt the course of cancer. Our research and development efforts are dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.
Location: United States, New Jersey, Cranbury
Employees: 51-200
Total raised: $236M
Founded date: 2013
Investors 4
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
| - | InterWest ... | interwest.... |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 04.08.2020 | Series D | $70M | - |
| 13.11.2019 | Series C | $62M | - |
| 27.02.2017 | Series B | $74M | - |
| 02.12.2014 | Series A | $30M | - |
Mentions in press and media 17
| Date | Title | Description | Source |
| 10.05.2022 | PMV Pharmaceuticals Reports First Quarter 2022 Financial Res... | Oral presentation at 2022 ASCO annual meeting to highlight initial data from ongoing Phase 1/2 PYNNA... | globenewsw... |
| 04.08.2020 | PMV Pharma Closes $70M in Series D Financing | CRANBURY, NJ, PMV Pharmaceuticals announced the completion of a $70 million Series D financing rou... | vcnewsdail... |
| 04.08.2020 | PMV Pharma nabs $70M for tumor suppressor programs | PMV Pharmaceuticals is topping up its coffers—just eight months after raising $62 million in its ser... | fiercebiot... |
| 03.08.2020 | PMV Pharma Closes $70 Million in Series D Financing | CRANBURY, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology co... | citybizlis... |
| 03.08.2020 | PMV Pharma nabs $70M for tumor suppressor programs | PMV Pharmaceuticals is topping up its coffers—just eight months after raising $62 million in its ser... | fiercebiot... |
| 13.11.2019 | PMV Pharma Secures $62 Million in Series C Financing To Deve... | - | orbimed.co... |
| 27.02.2017 | PMV Pharma Secures $74M in Series B | CRANBURY, NJ, Leader in the discovery and development of p53-targeted small molecule drugs for the... | vcnewsdail... |
| 24.02.2017 | Term Sheet — Friday, February 24 | FRIDAY! Scoop: Roku is in advanced discussions to raise at least $200 million in new funding at a po... | fortune.co... |
| 22.02.2017 | PMV Pharma gets a whopping $74M round to test a new p53 dr... | Arnold Levine Mutant p53 proteins have been one of the biggest — and most frustrating — targets... | endpts.com... |
| 22.02.2017 | PMV Pharma gets $74M boost for personalized chemistry | It wields a variety of anticancer mechanisms, including DNA repair and programmed cell death. That m... | medcitynew... |
Show more